For the Inventor, By the Inventor

Enter assignee name

Wilmington, DE, United States of America

Dupont Pharmaceuticals Company

USPTO Granted Patents = 106

Trademarks = 5

Forward Citations = 1,889

Loading Chart...

Loading Chart...

181 inventors (with patents filed for the assignee):

Paul Joseph Gilligan (10 out of 47 patents)

Mimi Lifen Quan (9 out of 82 patents)

Pasquale N Confalone (8 out of 25 patents)

4. Robert J Chorvat (7 out of 48 patents)

5. John Matthew Fevig (7 out of 36 patents)

6. Argyrios Georgios Arvanitis (7 out of 13 patents)

7. Joseph M Fortunak (7 out of 12 patents)

8. Rajagopal Bakthavatchalam (6 out of 40 patents)

9. Qi Han (6 out of 23 patents)

10. Philip Ma (6 out of 19 patents)

11. James Peter Beck (6 out of 13 patents)

12. Rodney Lawrence Parsons, Jr (6 out of 6 patents)

13. Hui-Yin Li (5 out of 34 patents)

14. Donald J Pinto (5 out of 18 patents)

15. Celia Dominguez (5 out of 15 patents)

Core Competencies:

Beta Protein Inhibitors

Cyclin Dependent Kinase Inhibitors

HIV Protease Inhibitors

Metalloprotease Inhibitors

Corticotropin Releasing Factor Antagonists

Ultrasound Contrast Agents

Radiopharmaceuticals

Factor Xa Inhibitors

Fast-Dissolving Formulations

Integrin Inhibitor Prodrugs

Neurological Disorder Treatments

Asymmetric Cyclic Ureas

106 patents: Sort by Forward Citations

1. 6887671 - Filtrate plate device and reversible-well plate device (2005-05-03),

2. 6713476 - Substituted cycloalkyls as inhibitors of a beta protein production (2004-03-30),

3. 6635430 - Filtrate plate device and reversible-well plate device (2003-10-21),

4. 6632812 - Substituted lactams as inhibitors of A&bgr; protein production (2003-10-14),

5. 6559152 - 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors (2003-05-06),

6. 6531477 - 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors (2003-03-11),

7. 6342503 - 1N-alkyl-n-arylpyrimidinamines and derivatives thereof (2002-01-29),

8. 6339099 - Guanidine mimics as factor Xa inhibitors (2002-01-15),

9. 6326368 - Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof (2001-12-04),

10. 6322770 - Indazole vitronectin receptor antagonist pharmaceuticals (2001-11-27),

11. 6319937 - Isoxazoline fibrinogen receptor antagonists (2001-11-20),

12. 6313124 - Tetrazine bicyclic compounds (2001-11-06),

13. 6313110 - Substituted 2H-1,3-diazapin-2-one useful as an HIV protease inhibitor (2001-11-06),

14. 6307044 - Process for the preparation of macrocyclic metalloprotease inhibitors (2001-10-23),

15. 6306886 - Crystalline roxifiban (2001-10-23),

Dupont Pharmaceuticals Company is a leading pharmaceutical company specializing in the research, development, and manufacturing of innovative healthcare solutions. With a strong focus on scientific excellence, we strive to improve the health and well-being of individuals worldwide. Our extensive portfolio includes a wide range of prescription medications, over-the-counter drugs, and healthcare products that address various therapeutic areas. At Dupont Pharmaceuticals, we believe in driving advancements in medical science to deliver effective and safe remedies for patients. Visit our website to learn more about our products, research initiatives, and commitment to improving global healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

106 Patents

#53 in Wilmington, DE

#69 in Delaware

#3,459 in US

#7,196 in the World

Wilmington, DE, United States of America

Dupont Pharmaceuticals Company

Forward Citations = 1,889

181 inventors:

Paul Joseph Gilligan (10 out of 47 patents)

Mimi Lifen Quan (9 out of 82 patents)

Pasquale N Confalone (8 out of 25 patents)

4. Robert J Chorvat (7 out of 48 patents)

5. John Matthew Fevig (7 out of 36 patents)

Please report any incorrect information to support@idiyas.com

Loading…